NASDAQ: SNDXSyndax Pharmaceuticals Inc Stock
$20.79-0.18 (-0.86%)
Updated Apr 24, 2024
SNDX Price
$20.79
Fair Value Price
$4.17
Market Cap
$1.77B
52 Week Low
$11.22
52 Week High
$25.34
P/E
-6.98x
P/B
3.19x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$209.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$161M
Beta
1.03
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SNDX Overview
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SNDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNDX ($20.79) is overvalued by 398.03% relative to our estimate of its Fair Value price of $4.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SNDX ($20.79) is not significantly undervalued (398.03%) relative to our estimate of its Fair Value price of $4.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SNDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SNDX due diligence checks available for Premium users.
Be the first to know about important SNDX news, forecast changes, insider trades & much more!
SNDX News
Valuation
SNDX fair value
Fair Value of SNDX stock based on Discounted Cash Flow (DCF)
Price
$20.79
Fair Value
$4.17
Overvalued by
398.03%
SNDX ($20.79) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SNDX ($20.79) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SNDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SNDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.98x
Industry
15.69x
Market
41.27x
SNDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.19x
Industry
5.86x
SNDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SNDX's financial health
Profit margin
Revenue
$0.0
Net Income
-$72.5M
Profit Margin
0%
SNDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$612.9M
Liabilities
$58.7M
Debt to equity
0.11
SNDX's short-term assets ($580.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNDX's short-term assets ($580.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNDX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SNDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$41.3M
Investing
-$16.3M
Financing
$258.5M
SNDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SNDX vs Biotech Stocks
Syndax Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.